These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15907546)

  • 21. Prospects for the development of pre-mortem laboratory diagnostic tests for Creutzfeldt-Jakob disease.
    Dabaghian RH; Mortimer PP; Clewley JP
    Rev Med Virol; 2004; 14(6):345-61. PubMed ID: 15495196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classification of sporadic Creutzfeldt-Jakob disease revisited.
    Cali I; Castellani R; Yuan J; Al-Shekhlee A; Cohen ML; Xiao X; Moleres FJ; Parchi P; Zou WQ; Gambetti P
    Brain; 2006 Sep; 129(Pt 9):2266-77. PubMed ID: 16923954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJD.
    Gould M
    BMJ; 2003 Oct; 327(7418):770. PubMed ID: 14525869
    [No Abstract]   [Full Text] [Related]  

  • 24. Update: Creutzfeldt-Jakob disease associated with cadaveric dura mater grafts--Japan, 1978-2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(42):1152-4. PubMed ID: 18946463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human cerebral organoids as a therapeutic drug screening model for Creutzfeldt-Jakob disease.
    Groveman BR; Ferreira NC; Foliaki ST; Walters RO; Winkler CW; Race B; Hughson AG; Zanusso G; Haigh CL
    Sci Rep; 2021 Mar; 11(1):5165. PubMed ID: 33727594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model.
    Collins SJ; Lewis V; Brazier M; Hill AF; Fletcher A; Masters CL
    Ann Neurol; 2002 Oct; 52(4):503-6. PubMed ID: 12325081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of pentosan polysulphate in cats with idiopathic, non-obstructive lower urinary tract disease: a double-blind, randomised, placebo-controlled trial.
    Wallius BM; Tidholm AE
    J Feline Med Surg; 2009 Jun; 11(6):409-12. PubMed ID: 18996037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues.
    Cordes H; Bergström AL; Ohm J; Laursen H; Heegaard PM
    J Immunol Methods; 2008 Sep; 337(2):106-20. PubMed ID: 18657541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is vaccination against transmissible spongiform encephalopathy feasible?
    Wisniewski T; Chabalgoity JA; Goni F
    Rev Sci Tech; 2007 Apr; 26(1):243-51. PubMed ID: 17633306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Neuroimaging in the diagnosis of human transmissible spongiform encephalopathies].
    Moreno F; Arriola Larrarte L
    Neurologia; 2006 Oct; 21(8):428-36. PubMed ID: 17013788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tauopathy in human and experimental variant Creutzfeldt-Jakob disease.
    Giaccone G; Mangieri M; Capobianco R; Limido L; Hauw JJ; Haïk S; Fociani P; Bugiani O; Tagliavini F
    Neurobiol Aging; 2008 Dec; 29(12):1864-73. PubMed ID: 17560687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different prion conformers target the olfactory pathway in sporadic Creutzfeldt-Jakob disease.
    Zanusso G; Ferrari S; Benedetti D; Sbriccoli M; Rizzuto N; Monaco S
    Ann N Y Acad Sci; 2009 Jul; 1170():637-43. PubMed ID: 19686205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second vCJD patient to receive experimental treatment.
    Dyer C
    BMJ; 2003 Oct; 327(7420):886. PubMed ID: 14563724
    [No Abstract]   [Full Text] [Related]  

  • 34. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies.
    Manuelidis L
    J Cell Biochem; 2007 Mar; 100(4):897-915. PubMed ID: 17044041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Creutzfeldt-Jakob disease: an emergency department presentation of a rare disease.
    Prince LA; Mann D; Reilly T
    J Emerg Med; 2006 Jul; 31(1):41-4. PubMed ID: 16798153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The first patient with the new variant of Creutzfeldt-Jakob's disease in The Netherlands].
    Jansen C; Houben MP; Hoff JI; Sanchez-Juan P; Rozemuller AJ; van Duijn CM
    Ned Tijdschr Geneeskd; 2005 Dec; 149(53):2949-54. PubMed ID: 16425845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Eleven years of autopsy on account of Creutzfeldt-Jakob disease in the Netherlands].
    Jansen C; Schuur M; Spliet WG; van Gool WA; van Duijn CM; Rozemuller AJ
    Ned Tijdschr Geneeskd; 2009; 153():A172. PubMed ID: 19785859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Young-onset CJD: age and disease phenotype in variant and sporadic forms.
    Corato M; Cereda C; Cova E; Ferrarese C; Ceroni M
    Funct Neurol; 2006; 21(4):211-5. PubMed ID: 17367581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CJD PrPsc removal by nanofiltration process: application to a therapeutic immunoglobulin solution (Lymphoglobuline).
    Truchot L; Arnaud T; Bloy C; Perret-Liaudet A
    Biologicals; 2006 Sep; 34(3):227-31. PubMed ID: 16490361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease.
    Hilton DA
    J Pathol; 2006 Jan; 208(2):134-41. PubMed ID: 16362983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.